Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
448788
Reference Type
Journal Article
Title
Diabetic cardiomyopathy: Insights into pathogenesis, diagnostic challenges, and therapeutic options
Author(s)
Aneja, A; Tang, WHW; Bansilal, S; Garcia, MJ; Farkouh, ME
Year
2008
Is Peer Reviewed?
1
Journal
American Journal of Medicine
ISSN:
0002-9343
EISSN:
1555-7162
Volume
121
Issue
9
Page Numbers
748-757
Language
English
DOI
10.1016/j.amjmed.2008.03.046
Abstract
Diabetic cardiomyopathy is the presence of myocardial dysfunction in the absence of coronary artery disease and hypertension. Hyperglycemia seems to be central to the pathogenesis of diabetic cardiomyopathy and to trigger a series of maladaptive stimuli that result in myocardial fibrosis and collagen deposition. These processes are thought to be responsible for altered myocardial relaxation characteristics and manifest as diastolic dysfunction on imaging. Sophisticated imaging technologies also have permitted the detection of subtle systolic dysfunction in the diabetic myocardium. In the early stages, these changes appear reversible with tight metabolic control, but as the pathologic processes become organized, the changes are irreversible and contribute to an excess risk of heart failure among diabetic patients independently of common comorbidities, such as coronary artery disease and hypertension. Therapeutic agents specifically targeting processes that lead to these pathophysiologic changes are in the early stages of development. Although glycemic control and early administration of neurohormonal antagonists remain the cornerstones of therapeutic approaches, newer treatment targets are currently being explored. (C) 2008 Elsevier Inc. All rights reserved.
Keywords
diabetes mellitus; diastolic dysfunction; heart failure; pathophysiology; treatment; ventricular diastolic dysfunction; endothelium-dependent relaxation; aldosterone receptor antagonists; converting enzyme-inhibition; congestive-heart-failure; protein-kinase-c; angiotensin-ii; doppler-echocardiography; cardiovascular health; insulin-resistance
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity